Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Weight Loss 1Thrombocytopenia 1Splenomegaly 1Smoldering Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fever 1Fatigue 1Anemia 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4fludarabine phosphate 3Epoetin Alfa 3Darbepoetin alfa 3Curcumin 3liposomal amphotericin B 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Fentanyl 2Cytogenetic Analysis 2Cyclosporine 2Caspofungin 2Carboplatin 2Busulfan 2Bortezomib 2Antilymphocyte Serum 2siltuximab 1sargramostim 1pyroxamide 1piperine 1isatuximab 1ferrous sulfate 1ferric gluconate 1alethine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Monoclonal Gammopathy of Undetermined Significance × Metformin × Plasma cell × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡